- Home
- NUAI vs PRQR Comparison
NUAI vs PRQR Comparison
Compare NUAI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUAI | PRQR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 167.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NUAI | PRQR |
|---|---|---|
| Price | $4.14 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 3.1M | 279.6K |
| Earning Date | 03-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $18.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $1.08 |
| 52 Week High | $9.45 | $3.10 |
Technical Indicators
Market Signals| Indicator | NUAI | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 36.93 |
| Support Level | $4.10 | $1.33 |
| Resistance Level | $5.16 | $1.58 |
| Average True Range (ATR) | 0.51 | 0.11 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 6.95 | 3.88 |
Price Performance
Historical ComparisonAbout NUAI New Era Energy & Digital Inc.
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.